Autotac Bio Overview

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $16.4M

  • Investors
  • 12

Autotac Bio General Information

Description

Developer of protein target decomposition drugs intended to develop therapeutics for humans. The company develops treatments for various rare and incurable diseases in addition to viral infections, including cancers, degenerative brain diseases, amyloid diseases, autoimmunity, and coronavirus, using autophagy-based target decomposition technology, enabling pharmaceutical companies to focus on improving the health of patients.

Contact Information

Website
autotacbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th floor, 254
  • Changgyeonggung-ro, Jongno-gu
  • Seoul, 03077
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 5th floor, 254
  • Changgyeonggung-ro, Jongno-gu
  • Seoul, 03077
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Autotac Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series B) 09-Apr-2022 $16.4M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Feb-2019 Completed Startup
To view Autotac Bio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Autotac Bio Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • 5

    Granted

  • Pending

  • Expiring in next 12 mo

Autotac Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-10391067-B2 Prevention and treatment of neurodegenerative diseases through autophagy activity mediated by a synthetic ligand or arginylated bip binding to the p62 zz domain Active 18-Aug-2015
US-20180243244-A1 Prevention and treatment of neurodegenerative diseases through autophagy activity mediated by a synthetic ligand or arginylated bip binding to the p62 zz domain Active 18-Aug-2015
EP-3338787-A1 Prevention and treatment of neurodegenerative diseases through autophagy activity mediated by ligand or arginylated bip binding to p62 zz domain Active 18-Aug-2015
EP-3338787-A4 Prevention and treatment of neurodegenerative diseases through autophagy activity mediated by ligand or arginylated bip binding to p62 zz domain Active 18-Aug-2015
EP-3338787-B1 Prevention and treatment of neurodegenerative diseases through autophagy activity mediated by ligand or arginylated bip binding to p62 zz domain Active 18-Aug-2015 A61K31/138
To view Autotac Bio’s complete patent history, request access »

Autotac Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Autotac Bio Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
AJU IB Investment Venture Capital Minority
Daekyo Investment Corporate Venture Capital Minority
DAYLI Partners Venture Capital Minority
DS Asset Management Asset Manager Minority
ILJIN Life Science Other Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Autotac Bio FAQs

  • Where is Autotac Bio headquartered?

    Autotac Bio is headquartered in Seoul, South Korea.

  • What is the size of Autotac Bio?

    Autotac Bio has 5 total employees.

  • What industry is Autotac Bio in?

    Autotac Bio’s primary industry is Drug Discovery.

  • Is Autotac Bio a private or public company?

    Autotac Bio is a Private company.

  • What is Autotac Bio’s current revenue?

    The current revenue for Autotac Bio is .

  • How much funding has Autotac Bio raised over time?

    Autotac Bio has raised $21M.

  • Who are Autotac Bio’s investors?

    AJU IB Investment, Daekyo Investment, DAYLI Partners, DS Asset Management, and ILJIN Life Science are 5 of 12 investors who have invested in Autotac Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process